Covalently dimerized Camelidae antihuman TNFa single-domain antibodies expressed in yeast Pichia pastoris show superior neutralizing activity

Applied Microbiology and Biotechnology

Volumn 97, Issue 19, 2013, Pages 8547-8558

  Ji, Xuemei ^a   Lu, Wuguang ^b   Zhou, Huiting ^a   Han, Dongju ^a   Yang, Lin ^a   Wu, Haitao ^a   Li, Jianfeng ^a   Liu, Hongyan ^a   Zhang, Jie ^a   Cao, Peng ^b   Zhang, Shuangquan ^a  

^a NANJING NORMAL UNIVERSITY   (China)

^b Jiangsu Province Institute of Traditional Chinese Medicine   (China)

Author keywords

Escherichia coli; Pichia pastoris; TNFa nanobody

Indexed keywords

ANTIBODIES; CELL DEATH; CLONING; COVALENT BONDS; DIMERS; DISEASES; ESCHERICHIA COLI; SULFUR COMPOUNDS;

CYTOTOXICITY ASSAYS; DISULFIDE BOND FORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATORY DISEASE; NANOBODY; PICHIA PASTORIS; SINGLE-DOMAIN ANTIBODIES; TUMOR NECROSIS FACTOR ALPHA;

YEAST;

COMPLEMENTARY DNA; DIMER; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN HEAVY CHAIN; MONOMER; NANOBODY; PROTEIN A; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIBODY; ENZYME; ENZYME ACTIVITY; PROTEIN; RECOMBINATION; STRAIN; TUMOR; YEAST;

ANIMAL CELL; ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL STRAIN L 929; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FLOW CYTOMETRY; IMMUNOGLOBULIN VARIABLE REGION; MASS SPECTROMETRY; NANOTECHNOLOGY; NONHUMAN; PICHIA PASTORIS; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DOMAIN;

CAMELIDAE; ESCHERICHIA COLI; MURINAE; PICHIA PASTORIS;

ANIMALS; ANTIBODIES, NEUTRALIZING; CAMELS; HUMANS; MICE; MOLECULAR WEIGHT; PICHIA; PROTEIN MULTIMERIZATION; RECOMBINANT FUSION PROTEINS; SINGLE-DOMAIN ANTIBODIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885382205     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-012-4639-2     Document Type: Article

References (44)

1. Aggarwal BB, Gupta SC, Kim JH (2012) Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119(3):651-665
2. Ahmadvand D, Rasaee MJ, Rahbarizadeh F, Mohammadi M (2008) Production and characterization of a high-affinity nanobody against human endoglin. Hybridoma Larchmt 27(5):353-360
3. Ameloot P, Brouckaert P (2004) Production and characterization of receptor-specific TNF muteins. Methods Mol Med 98:33-46
4. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414(3):521-526
5. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343(22):1586-1593
6. Baud V, Karin M (2001) Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11(9):372-377
7. Cao P, Zhang S, Gong Z, Tang X, Cao M, Hu Y (2006) Development of a compact anti-BAFF antibody in Escherichia coli. Appl Microbiol Biotechnol 73(1):151-157
8. Cao P, Zhang S, Fang Z, Huang H, Bai P, Zhang Q, Luo C (2008) Generation of a fusion protein of the extracellular domain of BR3 with the Fc fragment of human IgG1 (sBR3-Fc) in Pichia pastoris as an antagonist for BLyS. Appl Microbiol Biotechnol 78(2):275-282
9. Chauhan AK, Arora D, Khanna N (1999) A novel feeding strategy for enhanced protein production by fed-batch fermentation in recombinant Pichia pastoris. Process Biochem 34:139-145
10. Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, Hostens J, Revets H, Remaut E, Elewaut D, Rottiers P (2006) Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 54(6):1856-1866
11. Els Conrath K, Lauwereys M, Wyns L, Muyldermans S (2001a) Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 276(10):7346-7350
12. Els Conrath K, Lauwereys M, Wyns L, Muyldermans S (2001b) Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 276(10):7346-7350
13. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372(9636):375-382
14. Estell D (2006) Adapting industry practices for the rapid, large-scale manufacture of pharmaceutical proteins. Bridge 36:39-44
15. Ezzine A, M'Hirsi El Adab S, Bouhaouala-Zahar B, Hmila I, Baciou L, Marzouki MN (2012) Efficient expression of the anti-AahI′ scorpion toxin nanobody under a new functional form in a Pichia pastoris system. Biotechnol Appl Biochem 59(1):15-21
16. Floss DM, Kipriyanov S, Conrad U, Scheller J (2009) Covalent dimerization of Camelidae anti-human TNF-alpha single domain antibodies by the constant kappa light chain domain improves neutralizing activity. Biotechnol Bioeng 106(1):161-166
17. Frenken LG, van der Linden RH, Hermans PW, Bos JW, Ruuls RC, de Geus B, Verrips CT (2000) Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol 78(1):11-21
18. Freyre FM, Vazquez JF, Ayala M, Canaan-Haden L, Bell H, Rodriquez I, Gonzalez A, Cintado A, Gavilondo JV (2000) Very high expression of an anti-carcinoembryonic antigen single chain Fv antibody fragment in the yeast Pichia pastoris. J Biotechnol 76:157-163
19. Harmsen MM, De Haard HJ (2007) Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 77(1):13-22
20. Harmsen MM, Van Solt CB, Fijten HP, Van Setten MC (2005) Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. Vaccine 23(41):4926-4934
21. Jauregui-Amezaga A, Turon F, Ordas I, Gallego M, Feu F, Ricart E, Panes J (2012) Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis. doi: 10.1016/j.crohns.2012.05.012
22. Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, Perfetto EM (2002) Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 8(3):231-240
23. McMahon MS, Ueki Y (2008) Does anti-TNF-alpha have a role in the treatment of osteoporosis? Bull NYU Hosp Jt Dis 66(4):280-281
24. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356(9227):385-390
25. Migliore A, Massafra U, Carloni E, Padalino C, Martin Martin S, Lasaracina F, Dibiase N, Alimonti A, Granata M (2005) TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report. Eur Rev Med Pharmacol Sci 9(6):373-378
26. Mitoma H, Horiuchi T, Hatta N (2005) Infliximab induces potent antiinflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128(2):376-392
27. Muyldermans S, Baral TN, Retamozzo VC, De Baetselier P, De Genst E, Kinne J, Leonhardt H, Magez S, Nguyen VK, Revets H, Rothbauer U, Stijlemans B, Tillib S, Wernery U, Wyns L, Hassanzadeh-Ghassabeh G, Saerens D (2009) Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol 128(1-3):178-183
28. Nixon R, Bansback N, Brennan A (2007) The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology Oxford 46(7):1140-1147
29. Olichon A, Schweizer D, Muyldermans S, de Marco A (2007) Heating as a rapid purification method for recovering correctly-folded thermotolerant VH and VHH domains. BMC Biotechnol 7:7
30. Plagmann I, Chalaris A, Kruglov AA, Nedospasov S, Rosenstiel P, Rose-John S, Scheller J (2009) Transglutaminase-catalyzed covalent multimerization of Camelidae anti-human TNF single domain antibodies improves neutralizing activity. J Biotechnol 142(2):170-178
31. Powers DB, Amersdorfer P, Poul MA, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD (2001) Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods 251:123-135
32. Rahbarizadeh F, Ahmadvand D, Sharifzadeh Z (2011) Nanobody; an old concept and new vehicle for immunotargeting. Immunol Invest 40(3):299-338
33. Reff ME, Heard C (2001) A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol 40(1):25-35
34. Ridder R, Schmitz R, Legay F, Gram H (1995) Generation of rabbit monoclonal antibody fragments from a combinatorial phage display library and their production in the yeast Pichia pastoris. Biotechnology N Y 13(3):255-260
35. Rigby WF (2007) Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol 3(4):227-233
36. Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, De Haard HJ, Henegouwen PM VBe (2007) Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol Immunother 56(3):303-317
37. Sberna GCR, Henry A, Small DH (1996) Advantages of the methylotrophic yeast Pichia pastoris for high-level expression and purification of heterologous proteins. Austral Biotechnol 6:282-287
38. Sevastsyanovich Y, Alfasi S, Cole J (2009) Recombinant protein production: a comparative view on host physiology. N Biotechnol 25(4):175-180
39. Son JH, Cha SW (2010) Anti-TNF-alpha therapy for ankylosing spondylitis. Clin Orthop Surg 2(1):28-33
40. Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, Zack DJ, Fiorentino D (2012) Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 71(7):1143-1150
41. Urra JM, Arteta M, Gomez-Caturla A, Garcia-Duran F (2001) A chimeric anti-TNFalpha monoclonal antibody (cA2) in vivo removes TNFalpha-producing cells in Crohn's disease. Hum Antibodies 10(2):91-94
42. Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E, Cuvelier C, Rottiers P (2009) Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 3(1):49-56
43. Viola F, Civitelli F, Di Nardo G, Barbato MB, Borrelli O, Oliva S, Conte F, Cucchiara S (2009) Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol 104(10):2566-2571
44. Wiedmann MW, Mossner J, Baerwald C, Pierer M (2009) TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Endocr Metab Immune Disord Drug Targets 9(3):295-314